Department of Neurosciences, Case Western Reserve University, Cleveland, Ohio, USA.
J Neurochem. 2014 Jul;130(1):115-25. doi: 10.1111/jnc.12706. Epub 2014 Apr 2.
Development of Alzheimer's disease (AD) has been linked to the de-regulation of estrogen and gonadotropins such as luteinizing hormone (LH). In this study, we found increases in AD pathology in the hippocampi of aged female 3xTg AD mice after ovariectomy that were unable to be reduced by estrogen therapy or down-regulation of serum LH levels. Despite the lack of effect of these treatments on AD pathology, down-regulation of serum LH but not estrogen improved factors associated with neuronal plasticity such as spatial memory, inhibition of glycogen synthase kinase-3 beta, expression of beta-catenin, and brain-derived neurotrophic factor transcription. Contrasting previous studies in younger mice, estrogen replacement was not able to rescue behavioral deficits, reduced glycogen synthase kinase-3 beta inhibition and increased hippocampal phosphorylation of tau. Of critical importance, serum LH was negatively correlated with brain LH in regions associated with spatial memory, and increases in brain LH correlated with cognitive improvement. This paralleled changes in human female AD brains which showed a significant reduction in brain LH mRNA compared to healthy age- and PMI-matched controls. Taken together, these findings should promote further research into the LH-dependent mechanisms associated with AD cognitive deficits as well as the effects of estrogen within the aged brain. In the aged triple transgenic Alzheimer's disease (AD) mouse model (3xAD-Tg), estrogen replacement after ovariectomy does not improve cognitive function, increases phosphorylated Tau levels and decreases inhibition of GSK3 beta. Luprolide acetate rescues ovariectomy-dependent cognitive function, increases signaling events associated with synaptic plasticity including GSK3 beta inhibition, but does not alter AD pathology. In the human AD female brain, luteinizing hormone (LH) mRNA levels are reduced. In the 3XAD-tg model, brain LH protein levels are reduced by ovariectomy and normalized by leuprolide acetate treatment. These treatment-dependent normalization of LH positively correlates with markers of neuroplasticity and cognitive improvement.
阿尔茨海默病(AD)的发展与雌激素和促性腺激素(如黄体生成素[LH])的失调有关。在这项研究中,我们发现,在卵巢切除后的老年雌性 3xTg AD 小鼠的海马体中,AD 病理学增加,而雌激素治疗或血清 LH 水平降低不能减少这种增加。尽管这些治疗对 AD 病理学没有影响,但 LH 而非雌激素的下调改善了与神经元可塑性相关的因素,如空间记忆、抑制糖原合酶激酶-3β、β-连环蛋白的表达和脑源性神经营养因子转录。与之前在年轻小鼠中的研究形成对比的是,雌激素替代不能挽救行为缺陷、减少糖原合酶激酶-3β抑制和增加海马体 Tau 的磷酸化。至关重要的是,血清 LH 与与空间记忆相关的脑区中的脑 LH 呈负相关,而脑 LH 的增加与认知改善相关。这与人类女性 AD 大脑中的变化相平行,与健康年龄和 PMI 匹配的对照组相比,大脑 LH mRNA 显著减少。综上所述,这些发现应该促进进一步研究与 AD 认知缺陷相关的 LH 依赖性机制以及雌激素在老年大脑中的作用。在卵巢切除后的老年三转基因阿尔茨海默病(AD)小鼠模型(3xAD-Tg)中,雌激素替代并不能改善认知功能,增加磷酸化 Tau 水平,并减少 GSK3β的抑制。亮丙瑞林乙酸酯挽救了卵巢切除依赖性认知功能,增加了与突触可塑性相关的信号事件,包括 GSK3β的抑制,但不改变 AD 病理学。在人类 AD 女性大脑中,黄体生成素(LH)mRNA 水平降低。在 3XAD-tg 模型中,脑 LH 蛋白水平因卵巢切除而降低,并通过亮丙瑞林乙酸酯治疗得到正常化。这些治疗依赖性的 LH 正常化与神经可塑性和认知改善的标志物呈正相关。